LogicBio Therapeutics, Inc. (LOGC): Price and Financial Metrics
GET POWR RATINGS... FREE!
LOGC Stock Summary
- LOGC has a higher market value than only 3.95% of US stocks; more precisely, its current market capitalization is $22,942,062.
- LogicBio Therapeutics Inc's stock had its IPO on October 19, 2018, making it an older stock than merely 11.1% of US equities in our set.
- The volatility of LogicBio Therapeutics Inc's share price is greater than that of 96.95% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to LogicBio Therapeutics Inc, a group of peers worth examining would be BLDP, SPRO, VERU, CYTK, and VYGR.
- Visit LOGC's SEC page to see the company's official filings. To visit the company's web site, go to www.logicbio.com.
LOGC Valuation Summary
- In comparison to the median Healthcare stock, LOGC's price/sales ratio is 1373.68% higher, now standing at 56.
- LOGC's EV/EBIT ratio has moved up 25.1 over the prior 35 months.
- LOGC's EV/EBIT ratio has moved up 25.1 over the prior 35 months.
Below are key valuation metrics over time for LOGC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LOGC | 2021-08-31 | 56.0 | 3.4 | -4.3 | -2.9 |
| LOGC | 2021-08-30 | 54.9 | 3.3 | -4.2 | -2.8 |
| LOGC | 2021-08-27 | 55.3 | 3.4 | -4.2 | -2.8 |
| LOGC | 2021-08-26 | 52.5 | 3.2 | -4.0 | -2.6 |
| LOGC | 2021-08-25 | 52.5 | 3.2 | -4.0 | -2.6 |
| LOGC | 2021-08-24 | 51.6 | 3.1 | -3.9 | -2.5 |
LOGC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LOGC has a Quality Grade of C, ranking ahead of 45.61% of graded US stocks.
- LOGC's asset turnover comes in at 0.04 -- ranking 336th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows LOGC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.040 | 1 | -2.039 |
| 2021-03-31 | 0.047 | 1 | -1.619 |
| 2020-12-31 | 0.063 | 1 | -1.754 |
| 2020-09-30 | 0.060 | 1 | -1.813 |
| 2020-06-30 | 0.036 | 1 | -1.663 |
| 2020-03-31 | 0.017 | 1 | -1.504 |
LOGC Price Target
For more insight on analysts targets of LOGC, see our LOGC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $18.80 | Average Broker Recommendation | 1.33 (Strong Buy) |
LOGC Stock Price Chart Interactive Chart >
LOGC Price/Volume Stats
| Current price | $0.35 | 52-week high | $5.15 |
| Prev. close | $0.39 | 52-week low | $0.34 |
| Day low | $0.35 | Volume | 328,900 |
| Day high | $0.40 | Avg. volume | 834,457 |
| 50-day MA | $0.46 | Dividend yield | N/A |
| 200-day MA | $1.86 | Market Cap | 11.55M |
LogicBio Therapeutics, Inc. (LOGC) Company Bio
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Latest LOGC News From Around the Web
Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.
Palisade Bio, Pharming lead healthcare gainers; LogicBio Therapeutics, Pardes among losersGainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Biosciences (NASDAQ:PRDS) -13%. Biofrontera (NASDAQ:BFRI) -12%. Midatech Pharma (NASDAQ:MTP) -11%. Hyperfine (NASDAQ:HYPR) -7%.... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
Gene-editing company shares drop by one-third after clinical holdThe FDA ordered the clinical hold after two of the four patients who had been dosed in the trial developed severe blood reactions. |
Why Did LogicBio Therapeutics Shares Plunge To 52-Week Low Today?The FDA has placed a clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA). The hold follows after two adolescent patients in the trial were diagnosed with thrombotic microangiopathy (TMA), a clinical syndrome defined by the formation of tiny clots in blood vessels. The Company is evaluating LB-001 in a Phase 1/2 trial to treat children with the rare metabolic disease methylmalonic acidemia, which res |
LogicBio Therapeutics Provides Update on LB-001 Clinical Development ProgramLogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold. The company will host a conference call and webcast this morning to discuss this update. |
LOGC Price Returns
| 1-mo | -28.19% |
| 3-mo | -51.06% |
| 6-mo | -84.85% |
| 1-year | -92.03% |
| 3-year | -97.03% |
| 5-year | N/A |
| YTD | -84.85% |
| 2021 | -69.72% |
| 2020 | 5.97% |
| 2019 | -30.77% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...